As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...

Aspen's sasineprocel is an autologous induced pluripotent stem cell (iPSC) derived dopaminergic neuron precursor cell (DANPC) ...

Japan’s health ministry has endorsed the first stem-cell therapy derived from induced pluripotent stem cells (iPSCs) for ...

Japan has approved two stem cell-based therapies for treating Parkinson's disease and heart failure in a world first, through ...

Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) technology and Cellipont Bioservices, a cell therapy contract development and ...

Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and ...

Century Therapeutics is positioned as a leading contender in developing a durable, once-and-done cure for type I diabetes mellitus (T1DM) using its hypoimmune iPSC-derived β-cell therapy, CNTY-813.

On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the ...

Japan’s move to conditionally approve two induced pluripotent stem cell derived therapies marks a significant development for ...

With iPSCs continuing to emerge as an important source of starting materials for cell therapy developers, it is crucial to tackle key remaining challenges relating to cell culture scalability and ...